Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Summary

The aim of this study is to assess the treatment effect of sacubitril valsartan versus conventional therapy for heart failure (HF) in admitted patients due to exacerbation of HF on the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) concentrations.

Timeline

Start

2021-12-27

Primary completion

2024-02-08

Completion

2025-03

Publications

• Doi S, Tanaka A, Kida K, Imai T, Ueda Y, Nakano Y, Kizaki Y, Fukuda D, Matsue Y, Akashi YJ, Node K; PREMIER Study Investigators. Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study. J Card Fail. 2026 Mar;32(3):573-582. doi: 10.1016/j.cardfail.2025.05.001. Epub 2025 May 17.
• Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I, Hisauchi I, Teragawa H, Yazaki Y, Moroi M, Ohashi K, Nagatomo D, Kubota T, Ijichi T, Ikari Y, Yonezu K, Takahashi N, Toyoda S, Toshida T, Suzuki H, Minamino T, Nogi K, Shiina K, Horiuchi Y, Tanabe K, Hachinohe D, Kiuchi S, Kusunose K, Shimabukuro M, Node K. In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial. Eur Heart J. 2024 Nov 8;45(42):4482-4493. doi: 10.1093/eurheartj/ehae561.

Drugs

Indications